Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
– Agreement supports commitment to patient access, affordability and innovation – TOKYO, August 31, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”)...
- Partnership supports the development of next-generation leaders contributing to a more sustainable society - - Summit scheduled to take place at the Tokyo International Forum from September 28...
Read more about Astellas Becomes Host City Partner for One Young World 2027 Tokyo Summit
- ASP2138's advancement into Phase 3 marks an important milestone in Astellas' commitment to advancing research in CLDN18.2 with its differentiated portfolio, spanning approved treatments and...
TOKYO, August 7, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) confirms it has submitted a New Drug Application (NDA) to Japan's Ministry of Health,...
View Q1/FY2026 Financial results and related materials.
- First and only treatment regimen for adults with MIBC, regardless of cisplatin eligibility, representing a platinum-free potential standard of care - - Broadened approval supported by Phase 3...
TOKYO, July 7, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the Center for Drug Evaluation (CDE) of the China National Medical...
- Approval based on Phase 3 EV-303 results demonstrating significant improvements in event-free survival and overall survival compared with surgery alone - - Despite curative-intent surgery,...
TOKYO, May 29, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, the “Company”) hereby announces that Dr. Andreas Busch, an Outside Director of the Company, has...
TOKYO, May 29, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, the “Company”) has noted that Institutional Shareholder Services Inc. (“ISS”), a proxy advisory...
Read more about Astellas’ View on ISS Voting Recommendations
- Company sets ambition to achieve pipeline-led, record-high revenues by the mid-2030s - - CSP2026 is a growth strategy that will deliver profitable growth and generate cash, accelerate...
- Positive opinion is based on data from the pivotal Phase 3 EV-303 trial showing a 60% reduction in the risk of disease recurrence, progression or death and a 50% reduction in the risk of death...
- 10 abstracts, including two oral presentations, reinforce Astellas’ long-term commitment to advancing oncology care - TOKYO, May 18, 2026 – Astellas Pharma Inc. (TSE: 4503, President and...
TOKYO, May 15, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “the Company”) announced that at the meeting of the Board of Directors held today, a resolution was...
TOKYO, May 15, 2026– Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “the Company”) today announced that at the meeting of the Board of Directors held today, a resolution...
Read more about Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme
- Avacincaptad pegol granted Priority Review status in China - TOKYO, May 15, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the...
TOKYO, May 14, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the submission of a Supplemental New Drug Application (sNDA) to Japan's...
Pooled post hoc analysis of GATHER1 and GATHER2 showed IZERVAY® (avacincaptad pegol intravitreal solution) reduced the risk of progressing to loss of driving eligibility compared with sham over...
TOKYO, April 27, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that it booked an impairment loss for intangible assets and recorded...
TOKYO, April 27, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the following personnel change in its Top Management, effective from...
TOKYO, April 27, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that at a meeting of its Board of Directors held today, it decided a...
TOKYO, April 24, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd....
Read more about Astellas Amends Settlement and License Agreement with MSN regarding Myrbetriq®
- Submission based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trial - - Building on the existing indication in cisplatin-ineligible muscle-invasive...
- Setidegrasib is an investigational, novel KRAS G12D-targeted protein degrader - - KRAS G12D mutations occur in approximately 40% of pancreatic ductal adenocarcinomas, with no approved targeted...
Follow us
